EUVIMEDEUVIMED entdecken
Crossref

Serum carcinoembryonic antigen levels as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with colorectal cancer

Jieyao Li, Dan Wang, Zhen Zhang, Kai Sun, Qingyang Lei, Xuan Zhao, Jianmin Huang, Liping Wang, Yi Zhang iD

The Journal of Immunology · 2025

DOI: 10.1093/jimmun/vkaf037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Jieyao Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Cytokine-Induced Killer Cells, Colorectal Neoplasms, Carcinoembryonic Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China, International Science, Technology and Innovation Cooperation project of State Key R&D program, International Science, Technology and Innovation Cooperation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cytokine-induced killer (CIK) cells, as an adoptive immunotherapy, are effective at treating colorectal cancer (CRC). However, whether an individual can benefit from CIK cell therapy remains unclear. In this study, we analyzed the long-term effects of CIK cell therapy and specifically the relationship between tumor-associated antigen expression and the survival benefit of CIK cell therapy in patients with CRC. We conducted a retrospective clinical study of 98 patients with CRC who were pathologically diagnosed between 2010 and 2014. Of the patients in the study, 48 received surgery and/or chemotherapy (control group), and 50 received CIK cell infusion with chemotherapy or surgery (CIK group). CIK cells exhibited significant antitumor activity, expressing high levels of CD107 and increasing the apoptosis of CRC cells in vitro. Survival analysis showed that adjuvant CIK cell immunotherapy improved overall survival (OS) and progression-free survival (PFS) of patients with CRC. Moreover, OS and PFS improved significantly, irrespective of the stage of the disease. Furthermore, CIK cell adjuvant therapy significantly increased OS and PFS in patients with carcinoembryonic antigen (CEA) levels lower than 5 ng/ml before surgery, but not in patients with CEA levels above 5 ng/ml. Univariate and multivariate analyses showed that CEA expression is an independent prognostic factor for OS and PFS in the CIK cell treatment group. Adjuvant CIK cell therapy is an effective strategy for prolonging OS and PFS in patients with CRC, especially in those with serum CEA levels below 5 ng/ml.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytokine-Induced Killer CellsColorectal NeoplasmsCarcinoembryonic AntigenImmunotherapy, AdoptiveBiomarkers, TumorHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultPrognosisAged, 80 and over

Stichwörter der Autor:innen

CEACIKcolorectal cancerimmunotherapyprognosis

Substanzen

Carcinoembryonic AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China.
  • State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, Henan, China.
  • Henan Key Laboratory for Tumor Immunology and Biotherapy, Zhengzhou, Henan, China.

ORCID-Profile: Yi Zhang

Förderung

  • National Natural Science Foundation of China
  • International Science, Technology and Innovation Cooperation project of State Key R&D program
  • International Science, Technology and Innovation Cooperation
  • State Key R&D
  • Central Government of Henan Province Guides Local Science and Technology Development Fund
  • Science and Technology Project of Henan Province

Zitieren

APA

Li, J., Wang, D., Zhang, Z., Sun, K., Lei, Q., Zhao, X., Huang, J., Wang, L., & Zhang, Y. (2025). Serum carcinoembryonic antigen levels as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with colorectal cancer. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf037

Vancouver

Li J, Wang D, Zhang Z, Sun K, Lei Q, Zhao X, et al. Serum carcinoembryonic antigen levels as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with colorectal cancer. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf037

BibTeX
@article{Li2025,
  author = {Li, Jieyao and Wang, Dan and Zhang, Zhen and Sun, Kai and Lei, Qingyang and Zhao, Xuan and Huang, Jianmin and Wang, Liping and Zhang, Yi},
  title = {Serum carcinoembryonic antigen levels as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with colorectal cancer},
  journal = {The Journal of Immunology},
  year = {2025},
  doi = {10.1093/jimmun/vkaf037}
}
Kostenlos starten →